Literature DB >> 6818153

[N-formimidoyl-thienamycin: in vitro activity in bacteria with resistance to beta-lactam antibiotics or gentamicin].

K Bartmann, R Tarbuc.   

Abstract

The minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of N-formimidoyl-thienamycin were determined for 25 strains each of Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens and Pseudomonas aeruginosa which were resistant to gentamicin and/or acylureido penicillins or cefotaxime, cefoperazone or moxalactam, and for 38 strains of the group D streptococci. The drug was very active against the most frequently encountered gram-negative resistant causative organisms of nosocomial infections. The MIC ranged from 0.25-1 mg/l for multiresistant Enterobacteriaceae, and from 0.5-4 mg/l for multiresistant P. aeruginosa. The group D streptococci (enterococci) showed a low MIC (median: 0.75 mg/l); the median of the MBC was greater than 64 mg/l, however.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6818153     DOI: 10.1007/bf01642300

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  70 in total

1.  In vitro comparison of third-generation cephalosporins, piperacillin, dibekacin, and other aminoglycosides against aerobic bacteria.

Authors:  L Pulliam; W K Hadley; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

2.  In vitro activity of piperacillin compared with that of carbenicillin, ticarcillin, ampicillin, cephalothin, and cefamandole against Pseudomonas aeruginosa and Enterobacteriaceae.

Authors:  P P Shah; D J Briedis; H G Robson; J P Conterato
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

3.  Comparison of activity and beta-lactamase stability of cefotaxime with those of six other cephalosporins.

Authors:  R P Mouton; G P Bongaerts; M van Gestel
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

4.  In vitro studies of piperacilin, a new semisynthetic penicillin.

Authors:  D J Winston; D Wang; L S Young; W J Martin; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

5.  Minimum inhibitory and bactericidal concentrations of 44 antimicrobial agents against three standard control strains in broth with and without human serum.

Authors:  L G Reimer; C W Stratton; L B Reller
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

6.  Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation.

Authors:  T Yoshida; S Matsuura; M Mayama; Y Kameda; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

7.  Comparative in vitro study in new cephalosporins.

Authors:  G P Bodey; V Fainstein; A M Hinkle
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

8.  Antimicrobial activity of cefmenoxime (SCE-1365).

Authors:  J M Stamm; R L Girolami; N L Shipkowitz; R R Bower
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

9.  In vitro antibacterial activity and susceptibility of cefsulodin, an antipseudomonal cephalosporin, to beta-lactamases.

Authors:  A King; K Shannon; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

10.  In vitro activity of LY127935.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

View more
  2 in total

Review 1.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

2.  Phagocytic function and antibody-dependent cellular cytotoxicity of human neutrophils in the presence of N-formimidoyl thienamycin.

Authors:  A B Rodriguez; C Barriga; M de la Fuente
Journal:  Agents Actions       Date:  1990-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.